Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Received Date ICMJE | March 20, 2009 | ||||||||
Last Updated Date | July 12, 2012 | ||||||||
Start Date ICMJE | March 2009 | ||||||||
Primary Completion Date | |||||||||
Current Primary Outcome Measures ICMJE | |||||||||
Original Primary Outcome Measures ICMJE | |||||||||
Change History | Complete list of historical versions of study NCT00867269 on ClinicalTrials.gov Archive Site | ||||||||
Current Secondary Outcome Measures ICMJE | |||||||||
Original Secondary Outcome Measures ICMJE | |||||||||
Current Other Outcome Measures ICMJE | |||||||||
Original Other Outcome Measures ICMJE | |||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia | ||||||||
Official Title ICMJE | Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia | ||||||||
Brief Summary | Background:
Objectives:
Eligibility:
Design:
|
||||||||
Detailed Description | Idiopathic CD4+ lymphocytopenia (ICL) is a disorder characterized by decreased numbers of circulating CD4+ T lymphocytes in the absence of known causes of CD4+ lymphocytopenia. ICL is defined as an absolute CD4+ T cell count of less than 300 cells/mL in a patient with no human immunodeficiency virus infection or known immunodeficiency syndrome. The causes and frequency of the disorder remain unknown. The condition is typically diagnosed when patients present with a serious infection. In this natural history protocol, we will evaluate patients with CD4+ T cell counts below 300 cells/microL. We propose to follow 100 patients for a minimum of 4 and maximum of 10 years, with a particular focus on the association between ICL and autoimmune disease. We will collect blood for immunologic, rheumatologic, and genetic testing in an effort to identify and understand the underlying defects that cause ICL and follow its course in a cohort of patients who will receive best standard therapy for opportunistic infections. |
||||||||
Study Type ICMJE | Observational | ||||||||
Study Design ICMJE | Time Perspective: Prospective | ||||||||
Biospecimen | |||||||||
Sampling Method | |||||||||
Study Population | |||||||||
Condition ICMJE |
|
||||||||
Intervention ICMJE | |||||||||
Study Group/Cohort (s) | |||||||||
Publications * |
|
||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Recruiting | ||||||||
Estimated Enrollment ICMJE | 100 | ||||||||
Completion Date | |||||||||
Primary Completion Date | |||||||||
Eligibility Criteria ICMJE |
To be eligible for this study, patients must satisfy all of the following inclusion criteria:
EXCLUSION CRITERIA: Patients will be ineligible for this study if they satisfy any of the following criteria:
|
||||||||
Gender | Both | ||||||||
Ages | 2 Years and older | ||||||||
Accepts Healthy Volunteers | No | ||||||||
Contacts ICMJE |
|
||||||||
Location Countries ICMJE | United States | ||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT00867269 | ||||||||
Other Study ID Numbers ICMJE | 090102, 09-I-0102 | ||||||||
Has Data Monitoring Committee | |||||||||
Responsible Party | |||||||||
Study Sponsor ICMJE | National Institute of Allergy and Infectious Diseases (NIAID) | ||||||||
Collaborators ICMJE | |||||||||
Investigators ICMJE |
|
||||||||
Information Provided By | National Institutes of Health Clinical Center (CC) | ||||||||
Verification Date | November 2011 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |